Compare TRVG & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVG | EDIT |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.1M | 206.0M |
| IPO Year | 2015 | 2016 |
| Metric | TRVG | EDIT |
|---|---|---|
| Price | $2.93 | $2.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.09 | ★ $4.50 |
| AVG Volume (30 Days) | 81.6K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | $16.98 | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $2.71 | $0.91 |
| 52 Week High | $5.83 | $4.54 |
| Indicator | TRVG | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 61.40 |
| Support Level | $2.79 | $2.01 |
| Resistance Level | $2.96 | $2.76 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 46.48 | 84.68 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and All other countries.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.